Skip to main content

NeuroPace Inc

For the period ended Dec 31, 2024. Filed Mar 4, 2025.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 4, 2025

NPCE$12.50-1.5%Stored close · as of Nov 6, 2026
See the whole filing, with its images and exhibits

Special Note About Forward-Looking Statements

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Annual Report on Form 10-K contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, about us and our industry that involve substantial risks and uncertainties. All statements regarding results or events that may occur in the future contained in this report, including statements regarding our future results of operations and financial condition, as well as expectations of management for future operations, are forward-looking statements. In some cases, you can identity forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would,” or the negative of these words or other similar terms or expressions.

We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements are subject to a number of risks, uncertainties, factors and assumptions more thoroughly described in the section titled “Risk Factors” contained in Part I, Item 1A in this Annual Report on Form 10-K and elsewhere in this Annual Report on Form 10-K. These risks are not exhaustive. Moreover, we operate in a very competitive and rapidly changing environment. New risks factors emerge from time to time, and it is not possible for our management to predict all risk factors nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ from those contained in, or implied by, any forward-looking statements.

You should not rely on these forward-looking statements as predictions of future events. We cannot assure you that the events and circumstances reflected in the forward-looking statements will be achieved or occur. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this Annual Report on Form 10-K or to conform these statements to actual results or to changes in our expectations, whether as a result of any new information, future events, changed circumstances or otherwise. Forward-looking statements contained in this Annual Report on Form 10-K include, but are not limited to, statements about:

our expected future growth;

our ability to accurately forecast demand for our products;

the rate and degree of market acceptance of our products;

coverage and reimbursement for procedures performed using our products, including pre-implant evaluations, implant procedures, and follow-up care;

the performance of third parties in connection with the manufacturing and development of our products, including single-source suppliers;

regulatory developments in the United States and in any foreign countries in which we may seek to do business;

renewing our distribution agreement with DIXI Medical USA Corp., or DIXI Medical, or entering into a new agreement on acceptable terms;

our ability to retain regulatory approval for our products or obtain regulatory approval for updates to our products, or new products or indications in the United States and in any foreign countries in which we may seek to do business;

our research and development for existing products and new products, including our conduct of ongoing and future clinical trials for our existing products;

our expectations with respect to our existing products and their ability to be used without modification in pediatric patients and in those with generalized epilepsy;

our reliance on third-party suppliers for product components, some of which are single source suppliers;

our ability to manufacture our products in conformity with FDA requirements and with regulatory requirements of any foreign countries in which we may seek to do business;

our ability to predict product performance, including battery life of our RNS device;

our expectations regarding the impact that our sales and marketing initiatives will have on our sales;

our ability to retain or scale our organizational culture;

the development, regulatory approval, efficacy and commercialization of competing products;

our ability to attract and retain members of our board of directors, senior management, or operational personnel;

our expectations regarding the period during which we will qualify as an emerging growth company under the JOBS Act and as a smaller reporting company under the federal securities laws;

our ability to develop and maintain our corporate infrastructure, including our ability to maintain an effective system of internal control;

our expectations regarding the impact of public health crises and geopolitical tensions, such as the Russia-Ukraine war and ongoing conflicts in the Middle East, on our business, our industry and the economy;

the impact of adverse economic conditions, including as a result of unfavorable global economic and political conditions, increased interest rates and inflation;

our financial performance and capital requirements; and

our expectations regarding our ability to obtain, maintain and enforce intellectual property protection for our products and technology, as well as our ability to operate our business without infringing, misappropriating or otherwise violating the intellectual property rights of others.

You should read this Annual Report on Form 10-K as well as the documents that we reference in, and have filed as exhibits to, this report with the understanding that our actual future results, levels of activity, performance and achievements may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements.

In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based on information available to us as of the date of this Annual Report on Form 10-K. While we believe that such information provides a reasonable basis for these statements, that information may be limited or incomplete. Our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely on them.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.